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Ovarian borderline surface epithelial neoplasms occur infrequently in the pediatric population. Preop-
erative diagnostic criteria include ultrasound and serum tumor markers with deﬁnitive diagnosis made
on pathologic examinations intraoperatively. Treatment typically involves resection of the tumor with an
emphasis on preserving fertility. Patients diagnosed with borderline tumors generally have a good
prognosis; however the possibility of recurrence remains. Two cases of 15 year-old females with
borderline ovarian tumors are presented that add to the current literature by highlighting the diagnosis,
clinical management, and follow-up postoperatively.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Ovarian neoplasms are rare in the pediatric population, ac-
counting for approximately 1% of all childhood malignancies [1]. Of
these, 20% are epithelial in origin with a signiﬁcant portion classi-
ﬁed as borderline ovarian tumors (BOTs), otherwise known as tu-
mors of low malignant potential, according to the World Health
Organization [2]. Given the rarity of pediatric BOTs, there are
limited studies available that characterize the diagnosis, clinical
management, and outcomes in these patients. The currently rec-
ommended standard of care is aimed to preserve fertility by
resecting all visible disease [3]. In this report, we describe two cases
of ovarian borderline surface epithelial neoplasms, one of mucinous
and one of serous histological subtype, with subsequent surgical
treatment and management.25, cancer antigen 125; AFP,
, International Federation of
one; CT, computed tomog-
n emission tomography.
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1.1. Case 1
A 15-year-old female presented with a 1 year history of inter-
mittent abdominal pain, distension, and constipation. Abdominal
pain worsened and increased in frequency, localized to the peri-
umbilical and left lower quadrant region 1 week prior to presen-
tation. Patient reported normal menses without nausea or
vomiting. Ultrasound of the pelvis and abdomen revealed a large
cystic mass to be approximately 34  23  12 cm (Fig. 1A and B) in
size with internal septations, nodularity, and most likely ovarian
in etiology. Serum concentration of cancer antigen 125 was
elevated (CA 125, 41 U/mL; normal, <34 U/mL) and alpha-feto-
protein (AFP), lactate dehydrogenase (LDH), and beta-hCG were
within the normal range. On laparotomy, a large cystic structure
occupying most of the abdominal cavity was apparent originating
from the right ovary (Fig. 1C). Left ovary appeared to be within
normal limits. An ultrasound bag with Dermabond was placed on
the dried right ovarian wall to produce a water-tight barrier
through which a Veress needle was inserted and clear cystic ﬂuid
was suctioned [4]. Once the ovary was decompressed it was
brought through the umbilical incision (Fig. 1D) and the rest of thes reserved.
M. Canfarotta et al. / J Ped Surg Case Reports 2 (2014) 468e472 469cystic structure was separated from the fallopian tube with a
Harmonic scalpel. The fallopian tube was returned into the
abdomen before incision closure. Pathological examination of the
right ovarian cyst conﬁrmed a mucinous borderline tumor clas-
siﬁed by the International Federation of Gynecology and Obstet-
rics (FIGO) as stage IA with foci of epithelial proliferation,
stratiﬁcation, and mild to moderate cytologic atypia without
intraepithelial carcinoma or stromal invasion (Fig. 2). An omental
biopsy was not performed as the cystic ﬂuid appeared to be simple
and serous consistent with a benign ovarian cyst. Peritoneal
washings were acellular and negative for malignant cells.
The patient was discharged from the hospital on the 2nd day
postoperatively without any complications. Anti-mullerian hor-
mone (AMH) was normal 2 weeks postoperatively and by 1 month
serum concentrations of CA 125 normalized with the 3 month
follow-up ultrasound showing no residual mass or acute intra-
abdominal or intra-pelvic processes.1.2. Case 2
A 15-year-old female presented with 6e8 weeks of abdominal
distension and discomfort. Last menstrual period was reported to
have heavier ﬂow with more cramping pain than usual. No nausea,
vomiting, constipation, or fever. Abdominal and pelvic ultrasound
revealed a large cystic mass superior to the bladder measuring
approximately 23  18.3  8.8 cm presumably arising from the
right ovary (Fig. 3A and B). The left ovary was visualized posterior to
the uterus with a cyst measuring 5 cm at the maximal diameter
(Fig. 3C). Mild bilateral hydronephrosis was noted. CA 125, AFP, and
beta-hCG were within normal limits. On laparoscopy, bilateral
ovarian masses were noted with the right signiﬁcantly larger than
the left. At this time, a decision was made to proceed to an open
procedure through a Pfannestiel incision and a bilateral ovarian
tissue sparing oophorectomy was performed. Remaining ovarian
tissue was conﬁrmed by frozen section to be negative for tumor.
Peritoneal washings showed a few groups of atypical cells andFig. 1. (A) Longitudinal and (B) transverse ultrasound shows a large cystic mass to be appr
decompressed and pulled through the umbilical incision site. White arrows indicate cysticomental biopsy was negative for tumor. Pathological examination
of the cystically dilated ovaries revealed bilateral serous borderline
tumors, each of similar histology, classiﬁed as FIGO stage IB (Fig. 4A
and B).2. Discussion
Although BOTs are rare in the pediatric population, it is impor-
tant to be included in the differential diagnosis while evaluating
cystic masses in adolescent females. An algorithm outlining the
diagnosis, treatment, and management is provided (Fig. 5) and
subsequently discussed.
As we report 2 cases of BOTs with different histologic subtypes,
it is important to recognize geographic discrepancies in the dis-
cussion of incidence rates in certain populations. In a recent large
systematic review of adult BOTs, serous subtypes were more com-
mon in North America, Europe, and the Middle East, whereas
mucinous were more common in Eastern Asia [5]. The trend ap-
pears to be similar in childrenwith 40e70% characterized as serous
BOTs in North America [1,6,7] and in one of the largest series to
date, 89.7% were mucinous in a single center study in Korea [3].
However, further large series studies will be necessary to make
signiﬁcant inferences as literature regarding pediatric BOTs is
limited. It is also relevant to note that the serous subtype is more
commonly bilateral in adults (29.8% of serous and 7% of mucinous)
[8] with a similar incidence reported in the pediatric population
(30% of serous and 10% of mucinous) [9]. Albeit a small sample, our
report has some correlationwith a unilateral mucinous BOT (case 1)
and a synchronous bilateral serous BOT (case 2).
Clinical presentation in patients with ovarian masses typically
includes abdominal pain, distension, nausea, vomiting, and urinary
urgency. Although deﬁnitive diagnosis of a BOT is made intra-
operatively by pathological examination, serum tumormarkers and
imaging modalities can be of diagnostic use preoperatively. Many
ovarian tumors secrete markers that can be readily assayed in the
serum, such as AFP, beta-hCG, LDH, and CA 125. Of all markers, CAoximately 34  23  12 cm (C) visualized on laparotomy which was subsequently (D)
mass.
Fig. 2. Pathological examination of case 1 shows a stage IA mucinous borderline
ovarian tumor characterized by foci of epithelial proliferation, stratiﬁcation, and mild
to moderate cytologic atypia without intraepithelial carcinoma or stromal invasion
(H&E, 100).
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neoplasms. Although it has a low speciﬁcity for early ovarian tu-
mors and sensitivity for stage I disease, values greater than 35 U/mL
are generally good indicators of BOTs andmalignancies. Only one of
the patients reported had elevated levels of CA 125 and previous
literature has shown that these levels are elevated in 24e61% of
BOTs [10]. Serum LDH levels have been suggested as a non-speciﬁc
marker for malignancy [11], beta-hCG in the detection of neoplastic
processes associated with syncytiotrophoblasts, and elevated levels
of AFP associated with yolk sac tumors [12]. However, none of these
markers were elevated in either of the patients reported.
Along with tumor markers, the imaging technique of choice to
evaluate ovarian pathology is ultrasound. Benign tumors areFig. 3. (A) Longitudinal and (B) transverse ultrasound shows a large cystic mass approximate
located posterior to the uterus with a cyst measuring 5 cm in maximal diameter. White arrtypically characterized by smooth thin walls and few thin septa-
tions, whereas malignancies are generally larger soft tissue masses
with papillary projections and thick septations [13e16]. Further-
more, evidence has suggested that a morphologic scoring system
may be used to help differentiate benign from malignant adnexal
masses preoperatively in the pediatric population [15,17].
Computed tomography (CT) or magnetic resonance imaging (MRI)
may be useful when the origin of the mass is not readily seen by US.
Recent studies have also shown that positron emission tomography
(PET) may be beneﬁcial in the differentiation of borderline from
malignant tumors along with identiﬁcation of recurrent ovarian
cancer in the absence of a large mass with rising tumor marker
levels [18].
As the incidence of BOTs in the pediatric population is low,
guidelines are currently lacking and treatment plans tend to be
oriented toward adults, which involve surgical resection of the
tumor by either cystectomy or oophorectomy with the objective of
preserving childbearing potential [2,3,6]. Recurrence rates
following cystectomy have been shown to be higher than in
patients that undergo oophorectomy (12e58% and 0e20% respec-
tively) [19], suggesting that tumors involving the resection margin
may not be fully removed. However, studies in adults have shown
that contralateral relapse can occur at a similar rate following
conservative surgery, suggesting that tumor localization to the
other ovary may account for some cases of recurrence [20]. Despite
the higher recurrence rates with cystectomy, conservative treat-
ment is still suggested since there is no signiﬁcant difference in
survival outcomes, as future recurrences can be treated surgically
[20]. When considering surgical approach, most cases are per-
formed by laparotomy as there is concern for spillage in the lapa-
roscopic removal of adnexal masses suspicious for malignancy [21].
However, studies have shown that there is no signiﬁcant difference
in the rate of cystic rupture between techniques [22,23]. Full staging
of the disease requires tissue histology, cytologic analysis of peri-
toneal washings, and an omental biopsy in accordance with the
International Federation of Gynecologists and Obstetrics (FIGO),
which have been updated as of the beginning of 2014 [24]. A biopsy
of the omentum was not performed in case 1 as the ﬂuid appearedly 23  18.3  8.8 cm in size most likely originating from the right ovary. (C) Left ovary
ows indicate cystic masses.
Fig. 4. Pathological examination of case 2 shows histologically similar stage IB serous borderline tumor of the (A) left and (B) right ovary without microinvasion (H&E, 100x).
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future cases, given the lack of grossly discerning characteristics of
BOTs, we recommend omental biopsy even in cases with simple
ﬂuid. In mucinous BOTs, an appendectomy is also recommended
because of the possibility of a synchronous appendiceal lesion. In
case 1, after being diagnosed with a mucinous BOT, an appendec-
tomy was offered to the family as an additional treatment option
but they decided not to undergo further surgery. Other treatments
such as adjuvant chemotherapy have been used for advanced stage
diseasewithmixed results but have been shownnot to be beneﬁcial
in early stage BOTs [19].
The prognosis in these patients is considered to be very good,
however, with few studies available outlining the long-term out-
comes in pediatric BOTs; most data is extrapolated from adults. An
extensive review by Massad et al. showed that most adults presentFig. 5. Algorithm for the management of pediatric borderline ovarian tumors. BOT,
borderline ovarian tumor; CA 125, cancer antigen 125; LDH, lactate dehydrogenase;
AFP, alpha-fetoprotein.with stage I disease with a survival rate of nearly 100% [25]. In a
small study of children, Morris et al. showed similar results with
75% presenting with stage I disease with an overall survival of 100%
[26]. In a more recent study, Hazard et al. reported 83% of BOTs in
children presentedwith stage I diseasewith a 100% survival rate [1].
As literature regarding outcomes in pediatric BOTs is limited, there
are currently no guidelines for follow-up. However, in consider-
ation of recurrence in adults and children [3,6], we recommend at
least 10 years of monitoring with ultrasound and serum CA 125
levels every 3 months for the ﬁrst year, every 6 months for the
second year, and annually thereafter [1,2].
3. Conclusion
Herein, we report the diagnosis, treatment, and management of
2 adolescents with BOTs. These are rare tumors in the pediatric
population that generally have a good prognosis when diagnosed in
the early stages of disease but have a high rate of recurrence as
treatment involves surgical resection with the goal of preserving
fertility. Subsequently, long term follow-up of these patients is
important.
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